SCHEMBL4347353

SCHEMBL4347353

Oc1c(F)cccc1NC(=S)Nc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.58
ALDH1A1 P00352 4/20 0.58
LMNA P02545 3/20 0.58
MEN1 O00255 2/20 0.58
MAPT P10636 2/20 0.58
CYP3A4 P08684 2/20 0.57
HSD17B10 Q99714 2/20 0.57
TAS2R38 P59533 1/20 0.57
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
HPGD P15428 2/20 0.55
TP53 P04637 1/20 0.55
ALOX12 P18054 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
GAA P10253 1/20 0.53
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
MAPK1 P28482 2/20 0.50
HTT P42858 1/20 0.50
KDM4E B2RXH2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341741 0.86 KMT2A (0.54) KMT2AALDH1A1LMNAMEN1MAPT
SCHEMBL4348052 0.83 KMT2A (0.51) KMT2AALDH1A1LMNAMEN1MAPT
SCHEMBL4344475 0.82 RAB9A (0.57) KMT2AALDH1A1LMNAMEN1MAPT
SCHEMBL4344050 0.81 MAOB (0.56) KMT2AALDH1A1LMNAMEN1MAPT
SCHEMBL4348999 0.80 KMT2A (0.70) KMT2AALDH1A1LMNAMEN1MAPT
SCHEMBL4347312 0.80 ALDH1A1 (0.58) KMT2AALDH1A1LMNAMEN1MAPT
SCHEMBL4353757 0.80 KMT2A (0.60) KMT2AALDH1A1LMNAMAPTCYP3A4
SCHEMBL4341540 0.78 MEN1 (0.62) KMT2AALDH1A1LMNAMEN1MAPT
SCHEMBL4348536 0.78 LMNA (0.69) KMT2AALDH1A1LMNAMEN1MAPT
SCHEMBL4341294 0.77 ALDH1A1 (0.63) KMT2AALDH1A1LMNAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 KMT2A 2096/4885ALDH1A1 2565/4885LMNA 3160/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 KMT2A 1254/4885ALDH1A1 2767/4885LMNA 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.